Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.144.228.87
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Nephrology
Primary Hyperoxaluria
Trending Topics

Clinical Outcomes in Primary Hyperoxaluria Type 2

Posted on

Primary hyperoxaluria type 2 (PH2) is a rare disorder characterized by the overproduction oxalate, which can lead to kidney stones, can ultimately renal failure.

In this study, datasets from 101 patients from 11 counties found in the European Hyperoxaluria Consortium (OxalEurope)—the largest PH2 cohort—were included. First symptoms were reported at a median age of 3.2 years with a mean diagnosis for index cases at 8.0 years. There was a median follow-up of 12.4 years.

Approximately 82% of cases presented with urolithiasis. A genetic analysis identified 18 novel mutations in the GRHPR gene. Of 238 spoturine analyses, 23 (9.7%) were within normal range as compared to less than 4% of 24- hour urine collections. Median intra-individual variation of 24-hour oxalate excretion was substantial (34.1%).

-Advertisement-
-Advertisement-

Twelve patients were lost to follow-up and median renal survival was 43.3 years. Approximately 50% of patients experienced chronic kidney disease (CKD) stage ≥2 and 24.7% had reached CKD5.

There were a reported 15 transplantations in 11 patients. Renal outcome did not correlate with genotype, biochemical parameters, or with the presence of nephrocalcinosis at presentation.

The authors concluded that 24-hour urine analysis provides an accurate diagnosis of PH2 and that the role of liver transplantation remains unclear.

 

Reference

Garrelfs SF, Peters-Sengers H, Groothoff J, et al. Primary hyperoxaluria type 2: new insight into clinical outcomes. J Am Soc Nephrol 30. 2019; Kidney Week 2019 Supplement.

-Advertisement-
Related Articles
Optimizing Electronic Health Record Data for Diagnosing Rare Diseases
May 29, 2021
The American Society of Nephrology Offers Informational Webinar on New COVID-19 Guidance for Dialysis Facilities
Jun 02, 2020
Attendee at Kidney Conference Tests Positive for COVID-19
Jun 02, 2020
-Advertisement-